A previous study has reported that metformin inhibits TRIM18-dependent translation of the amyloid precursor protein, reduces amyloid-β plaque burden, and decreases tau phosphorylation, suggesting that TRIM18 can be used as a target for treating Alzheimer’s disease (Matthes et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.